Sarepta Therapeutics Inc (SRPT)

Return on assets (ROA)

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Net income (ttm)	US$ in thousands	16,897	-535,977	-690,876	-907,677	-1,115,218	-703,488	-716,225	-506,631	-356,555	-418,780	-486,116	-634,471	-703,886	-554,128	-600,514	-530,341	-655,924	-715,075	-620,267	-570,334
Total assets	US$ in thousands	3,224,380	3,264,580	3,109,710	3,125,890	3,059,790	3,128,370	3,156,150	2,996,850	3,056,150	3,147,970	2,662,220	2,759,070	2,765,230	2,984,720	2,780,660	2,883,040	2,947,390	1,822,820	1,702,470	1,747,750
ROA		0.52%	-16.42%	-22.22%	-29.04%	-36.45%	-22.49%	-22.69%	-16.91%	-11.67%	-13.30%	-18.26%	-23.00%	-25.45%	-18.57%	-21.60%	-18.40%	-22.25%	-39.23%	-36.43%	-32.63%

March 31, 2024 calculation

ROA = Net income (ttm) ÷ Total assets
= $16,897K ÷ $3,224,380K
= 0.52%

Sarepta Therapeutics Inc's return on assets (ROA) has shown significant fluctuations over the past few quarters. The ROA ranged from -39.23% to 0.52% during the period from June 2019 to March 2024. The negative ROA figures indicate that the company's net income is insufficient to cover its total assets, reflecting inefficiency in asset utilization.

The ROA improved slightly in the most recent quarter to 0.52% as of March 31, 2024, suggesting a potential increase in profitability relative to its asset base. However, the negative trend in previous quarters, with the lowest ROA recorded at -39.23% in March 2020, indicates persistent challenges in generating profits from its assets.

Investors and stakeholders should closely monitor Sarepta Therapeutics Inc's future financial performance to assess whether the recent improvement in ROA is sustainable and indicative of a positive turnaround in the company's operating efficiency.